%0 Journal Article
%T The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms.
%A Berentsen S
%A Vos JMI
%A Malecka A
%A Tjønnfjord GE
%A D'Sa S
%J Expert Rev Hematol
%V 0
%N 0
%D 2024 Jun 28
%M 38938203
%F 2.819
%R 10.1080/17474086.2024.2372333
%X <B>UNASSIGNED: </B>During the last decades, the pathogenesis of cold agglutinin disease (CAD) has been well elucidated and shown to be complex. Several documented or investigational therapies have been made available. This development has resulted in major therapeutic advances, but also in challenges in choice of therapy.<BR><B>UNASSIGNED: </B>In this review, we address each step in pathogenesis: bone marrow clonal lymphoproliferation, composition and effects of monoclonal cold agglutinin, non-complement mediated erythrocyte agglutination, complement-dependent hemolysis, and other effects of complement activation. We also discuss the heterogeneous clinical features and their relation to specific steps in pathogenesis, in particular with respect to the impact of complement involvement. CAD can be classified into three clinical phenotypes with consequences for established treatments as well as development of new therapies. Some promising future treatment approaches - beyond chemoimmunotherapy and complement inhibition - are reviewed.<BR><B>UNASSIGNED: </B>The patient's individual clinical profile regarding complement involvement and hemolytic versus non-hemolytic features is important for the choice of treatment. Further development of treatment approaches is encouraged, and some candidate drugs are promising irrespective of clinical phenotype. Patients with CAD requiring therapy should be considered for inclusion in clinical trials.